

# Decision Dx MELANOMA

## Will My Melanoma Come Back or Spread?

Talking With Your  
Healthcare Professional  
About DecisionDx<sup>®</sup>-Melanoma



**C/STLE**  
BIOSCIENCES

### Introduction

As with all cancers, one of the primary challenges for healthcare professionals in managing melanoma is predicting the course of their patients' disease, or prognosis. Having an accurate picture of whether your cancer is likely to come back or spread is critical to determining which treatment and follow-up plan is right for you.

If you have recently been diagnosed with melanoma, you may be eligible for DecisionDx<sup>®</sup>-Melanoma, a genomic test that identifies whether your melanoma has a low or high risk of recurrence (coming back) and your likelihood of having a positive sentinel lymph node. Knowing this information can help you and your healthcare team make more informed decisions about the treatment and management of your melanoma.

Use this guide to help you prepare for future discussions with your healthcare professional and determine if testing with DecisionDx-Melanoma is right for you.

### About DecisionDx-Melanoma

DecisionDx-Melanoma is a genomic test that uses a small sample of your melanoma tissue to measure the activity of 31 specific genes that can tell us how likely it is for the cancer to come back or spread within the next 5 years and your likelihood of sentinel lymph node positivity.

DecisionDx-Melanoma provides you and your healthcare professional with accurate, personalized information that traditional staging factors alone may miss.

DecisionDx-Melanoma test results can guide critical treatment and management plan decisions such as frequency of follow-up appointments, additional treatment options and whether you should consider or forgo a sentinel lymph node biopsy surgical procedure.

Check off the answers below and take this with you to your next scheduled appointment.

This will help you and your healthcare professional discuss and decide whether DecisionDx-Melanoma is right for you.

#### Please check all that apply

- I have been diagnosed with cutaneous (skin) melanoma.
- I was told my melanoma is Stage I, II or III.
- My healthcare professional told me I am eligible for a sentinel lymph node biopsy.
- I would like to have an individualized assessment of the likelihood of my cancer spreading to the rest of my body or coming back.

## Talking With Your Healthcare Professional About DecisionDx<sup>®</sup>-Melanoma


## DecisionDx-Melanoma Informs Patient Management Decisions

### AJCC Staging-Only Approach Misses Patients with Aggressive Tumor Biology

The majority of melanoma-related deaths occur in Stage I and II node negative patients originally thought to be “low risk” by standard prognostic criteria. There is a need to identify early-stage patients who may have aggressive tumor biology or a high risk of a positive node so that they can receive surgical intervention. The DecisionDx-Melanoma test uses an individual patient’s tumor biology to provide information on risk of recurrence and identify the likelihood of sentinel lymph node positivity beyond traditional clinical factors alone in early-stage disease.

DecisionDx-Melanoma identifies the individual risk of recurrence and metastasis including the likelihood of sentinel lymph node positivity among early-stage patients.

This personalized information informs two key clinical management decisions:




- 1** Intensity of follow up, surveillance imaging and referrals
- 2** Sentinel Lymph Node Biopsy (SLNB) patient selection

## Talking With Your Healthcare Professional About DecisionDx®-Melanoma

## Ordering DecisionDx-Melanoma

### Now Integrating Clinical and Pathologic Factors for a More Precise and Personalized Likelihood of SLN Positivity

Using a validated algorithm, a patient's clinical and pathologic factors are incorporated into an artificial intelligence trained algorithm with the DecisionDx-Melanoma result score. This integrated test result (i31-GEP) provides a more precise and personalized SLN positivity risk prediction, identifying patients with a low risk of SLN positivity who could potentially forgo the procedure and those patients at high risk of SLN positivity who should consider and be offered a SLNB.



### Simple Ordering Process

Only a healthcare professional can order DecisionDx-Melanoma. The following documents are required to order a test:

- DecisionDx-Melanoma Requisition Form (available at [CastleTestInfo.com](http://CastleTestInfo.com))
- Letter of medical necessity
- Pathology report of the primary biopsy (include excision report if available)
- Copy of patient's insurance information

Healthcare professionals can submit all documentation online through **Portal.CastleBiosciences.com** or fax to **866-329-2224**.

Castle Biosciences will work with the appropriate pathology group to coordinate specimen collection and shipping. Test results are typically available within 3-5 business days from receipt of the sample in our laboratory.